176
Participants
Start Date
March 2, 2017
Primary Completion Date
May 13, 2021
Study Completion Date
May 13, 2021
EryDex Low dose DSP
EDS-EP dose range of \~5-10 mg DSP/infusion
EryDex High dose DSP
EDS-EP dose range of \~14-22 mg DSP/infusion
Pooled Placebo
EDS processed autologous erythrocytes using a sodium chloride \[NaCl\] solution.
El Razi Hospital, Manouba
Laboratoriumgeneeskunde, Leuven
Royal Children's Hospital, Melbourne
U.O. Neurologia e Psichiatria dell'Infanzia e dell' Adolescenza. ASST Spedali Civili, Piazzale Spedali Civili, 1, Brescia
Sheba Medical Center, Tel Litwinsky
Klinik für Kinder- und Jugendmedizin Pädiatrische Allergologie, Pneumologie und Mukoviszidose, Universitätsklinikum Frankfurt, Frankfurt am Main
UT Health, Houston
All India Institute of Medical Sciences, New Delhi
PD Hinduja National Hospital and Medical Research, Mahīm
Jaslok Hospital and Research Centre, Mumbai
Nizam's Institute of Medical Sciences, Hyderabad
Vijaya Health Centre, Department of Neurology, Chennai
Amrita Institute of Medical Sciences and Research Centre, Kochi
UCLA-Ataxia Center and HD Center of Exellence, Los Angeles
The Ataxia-Telangiectasia Clinical Center, The Johns Hopkins Hospital, Baltimore
Cincinnati Children's Hospital Medical Center, Cincinnati
National Institute of Mental Health and Neurosciences, Bangalore
Dipartimento di Pediatria e Neuropsichiatria Infantile, Università Sapienza di Roma, Azienda Policlinico Universitario Umberto I, Rome
Norwegian National Unit for Newborn Screening, Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo
Hospital Universitario La Paz., Madrid
Nottingham University Hospitals NHS Trust - Queen's Medical Centre, Nottingham
Department of Clinical Immunology The Children's Memorial Health Institute, Warsaw
Quince Therapeutics S.p.A.
INDUSTRY